The integration of NT-proBNP as a routine biomarker in the clinical management of cancer patients receiving ICIs could lead to earlier identification of those at highest cardiovascular risk, enabling early intervention strategies, including closer monitoring, lifestyle modification, and, in certain cases, the prophylactic use of cardioprotective medications. Here, NPPB is linked to cancer.